Sejal joined Sonoma Biotherapeutics in 2020 with 15 years of experience managing global cross-functional teams and partnerships in biologics and gene therapy drug development.
She was most recently Executive Director, Research Operations overseeing early stage gene therapy programs and research pipeline strategy. Prior to that, she was in program and alliance management at Denali Therapeutics where she managed the company’s partnerships with F-star and Takeda and led several programs in the biologics portfolio. Earlier in her career, she was part of the leadership teams at iPierian and True North Therapeutics, responsible for fundraising and acquisition of both companies.
Sejal earned a Ph.D. in Chemical Engineering from UC Santa Barbara and B.S. in Chemical Engineering from MIT.